Phase i double- blind, placebo-controlled trial of 0.3MG linaclotide delayed-release (DR1) to demonstrate colorectal bioactivity in healthy volunteers
Ended Awarded Last action
- Contract number
- HHSN26100014
- Awardee
-
Mayo Clinic UEI Y2K4F9RPRRG7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $364,672
Award facts
- Opportunity
-
- N01CN0501469 Solicitation number
- Contract value 100% obligated
- $364,672.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Rochester, MN 55905, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$85,509 | |
| Change Order | $0 | |
| Exercise an Option | $206,377 | |
| Change Order | $0 | |
| Original award | $243,804 |
About this award
This is a $364,672.04 federal contract awarded by the National Cancer Institute (NCI) to Mayo Clinic, a large non-profit academic medical center, to conduct a Phase I double-blind, placebo-controlled trial of 0.3mg linaclotide delayed-release (DR1) to demonstrate colorectal bioactivity in healthy volunteers. The contract is a delivery order under the NCI's Cancer Prevention Agent Development Program: Early Phase Clinical Research program and does not have a set-aside designation. Mayo Clinic frequently supports federal initiatives through prime contracts, grants, and subcontractor arrangements, leveraging its expertise in clinical care, research, and education. This contract enables the NCI to efficiently access Mayo Clinic's capabilities in cancer drug development over multiple years through a $9.9 million Indefinite Delivery/Indefinite Quantity (IDIQ) contract awarded in 2021. The trial is being conducted in collaboration with Thomas Jefferson University Hospitals Inc., which is serving as a subcontractor on the project.
Quick answers
Who was awarded contract HHSN26100014?
HHSN26100014 was awarded to Mayo Clinic by National Cancer Institute (National Institutes of Health) on September 15, 2017.
How much is contract HHSN26100014 worth?
The government has obligated $364,672 on HHSN26100014.
Is contract HHSN26100014 an order under another contract?
Yes. HHSN26100014 is a delivery order under HHSN261201200042I, an indefinite delivery contract.
Was contract HHSN26100014 competed?
The extent of competition for HHSN26100014 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award